Chimeric antigen receptor T (CAR-T) cell therapy has emerged as a transformative approach in modern medicine, demonstrating remarkable efficacy in targeting pathogenic B-cell lineages with ...

As of April 2025, four CD19-directed chimeric antigen receptor (CAR)-T therapies and three CD20-targeting bispecific antibodies (BsAbs) have been US Food and Drug Administration (FDA) approved for the ...

A Phase 1 trial testing TG Therapeutics' CAR T-cell therapy azer-cel in progressive forms of MS is now recruiting across eight U.S. sites.

Obe-cel is the first FDA-approved CAR T-cell therapy for B-ALL without a REMS requirement, based on the FELIX trial's positive outcomes. The FELIX trial reported a 63% complete remission rate, with 42 ...

Researchers hope to undertake clinical studies in multiple cancers, including ovarian cancer, glioblastoma, and others.

Epstein-Barr virus (EBV) infected and reprogrammed autoreactive B cells in patients with systemic lupus erythematosus (SLE) to become activated antigen-presenting cells. EBV-infected B cells in ...

A new artificial intelligence (AI) tool can simultaneously assess blood samples for infections, autoimmune diseases, and vaccine responses, according to a new study. The algorithm analyzed genes ...

CAAR-T therapy may eliminate FVIII inhibitors in hemophilia A, potentially improving replacement treatment effectiveness, a study shows.